FibroBiologics Inc. Commo...

NASDAQ: FBLG · Real-Time Price · USD
0.94
0.09 (10.04%)
At close: Jun 06, 2025, 3:59 PM
0.97
3.53%
After-hours: Jun 06, 2025, 05:54 PM EDT

Company Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States.

It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing.

The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers.

FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

FibroBiologics Inc. Common Stock
FibroBiologics Inc. Common Stock logo
Country United States
IPO Date Feb 1, 2024
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Peter O'Heeron

Contact Details

Address:
455 East Medical Center Boulevard
Houston, Delaware
United States
Website https://www.fibrobiologics.com

Stock Details

Ticker Symbol FBLG
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001958777
CUSIP Number 31573L105
ISIN Number US31573L1052
Employer ID 86-3329066
SIC Code 2834

Key Executives

Name Position
Peter O'Heeron Founder, Chairperson & Chief Executive Officer

Latest SEC Filings

Date Type Title
May 27, 2025 4 Filing
May 14, 2025 10-Q Quarterly Report
May 05, 2025 8-K Current Report
Apr 23, 2025 ARS Filing
Apr 23, 2025 DEFA14A Filing
Apr 23, 2025 DEF 14A Filing
Mar 31, 2025 10-K Annual Report
Mar 28, 2025 4 Filing
Mar 28, 2025 4 Filing
Mar 28, 2025 4 Filing